Health technology company Juno Diagnostics has launched a non-invasive prenatal screening (NIPS) solution called Juno Hazel for genetic testing.

The Juno Hazel test uses the firm’s proprietary Sample Collection Kit to provide access to genetic testing from finger-prick amounts of blood.

According to the firm, this method enhances early access to high-quality genetic testing while avoiding the traditional NIPS’ high prices, long lead times, and phlebotomy requirements.

The combination of the Juno Hazel test with the Sample Collection Kit is said to enable fast production of blood plasma for further laboratory, thereby lowering costs, expanding accessibility, and enhancing the NIPS experience, said Juno Diagnostics.

The company stated that the new test screens for common chromosomal aberrations like trisomy 21, 18, and 13, with the option to report on additional clinical material.

Juno Diagnostics founder and chief CEO Dirk van den Boom said: “The launch of Juno Hazel represents a game-changing achievement for prenatal care that we believe will create a paradigm shift in NIPS.

“We are developing next-generation NIPS solutions that are highly accurate, affordable, and accessible to millions of women and families, delivering a higher standard of care.

“We see tremendous opportunity for our novel approach to blood-based testing, such as NIPS, and are excited to expand our commercial footprint beyond Juno Birch.”

The health technology firm aims to create a platform that will improve access to prenatal testing and information for pregnant women.

Juno Diagnostics plans to collaborate with doctors and genetic counsellors to enable a better level of prenatal care through Juno Hazel and NIPS offerings. The company seeks to add complementary products and services to its NIPS range.

Juno Diagnostics chief medical officer Mathias Ehrich said: “We spent the last few years building a foundation of exceptional science that catalyzed the high performance of Juno Hazel.

“Since then, we have demonstrated greater than ninety-nine percent (>99%) sensitivity and specificity to detect multiple chromosomal abnormalities.”